Reviva reports FY2025 net loss of $19.9M; FDA requires second Phase 3 trial for schizophrenia drug

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $19.9M ($5.48 per share) vs $29.9M ($17.73) in FY2024.
Cash and equivalents $14.4M at Dec 31, 2025; ~$23M after March 2026 offering, funding into Q1-2027.
FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia; initiation planned mid-2026.
Positive 1-year open-label extension data: sustained efficacy, benign weight gain (~1.5 kg), no motor side effects.
Completed public offerings totaling $29M in 2025 and early 2026; intends to fund RECOVER-2 trial.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-010140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.